BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 16454979)

  • 1. Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome.
    Chen YG; Xu F; Zhang Y; Ji QS; Sun Y; Lü RJ; Li RJ
    Chin Med J (Engl); 2006 Jan; 119(1):32-6. PubMed ID: 16454979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels.
    Vavuranakis M; Latsios G; Aggelis D; Bosinakou I; Karambelas I; Tousoulis D; Toutouzas K; Stefanadis C
    Clin Ther; 2006 Jun; 28(6):860-71. PubMed ID: 16860169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of clopidogrel plus aspirin on tissue perfusion and coronary flow in patients with ST-segment elevation myocardial infarction: a new reperfusion strategy.
    Dogan A; Ozgul M; Ozaydin M; Aslan SM; Gedikli O; Altinbas A
    Am Heart J; 2005 Jun; 149(6):1037-42. PubMed ID: 15976785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial.
    Dosh K; Berger PB; Marso S; van Lente F; Brennan DM; Charnigo R; Topol EJ; Steinhubl S
    Circ Cardiovasc Interv; 2009 Dec; 2(6):503-12. PubMed ID: 20031767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease.
    Solheim S; Pettersen AA; Arnesen H; Seljeflot I
    Thromb Haemost; 2006 Nov; 96(5):660-4. PubMed ID: 17080224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease.
    Azar RR; Kassab R; Zoghbi A; Aboujaoudé S; El-Osta H; Ghorra P; Germanos M; Salamé E
    Am Heart J; 2006 Feb; 151(2):521.e1-521.e4. PubMed ID: 16442924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial.
    Yong G; Rankin J; Ferguson L; Thom J; French J; Brieger D; Chew DP; Dick R; Eccleston D; Hockings B; Walters D; Whelan A; Eikelboom JW
    Am Heart J; 2009 Jan; 157(1):60.e1-9. PubMed ID: 19081397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.
    Cannon CP; Husted S; Harrington RA; Scirica BM; Emanuelsson H; Peters G; Storey RF;
    J Am Coll Cardiol; 2007 Nov; 50(19):1844-51. PubMed ID: 17980250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry.
    Lim MJ; Spencer FA; Gore JM; Dabbous OH; Agnelli G; Kline-Rogers EM; Dibenedetto D; Eagle KA; Mehta RH;
    Eur Heart J; 2005 Jun; 26(11):1063-9. PubMed ID: 15716281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of different doses of fluvastatin on inflammatory markers in the early phase of acute coronary syndrome.
    Yang J; Li XP; Zhao SP; Li J; Li JD; Xie XM
    Clin Chim Acta; 2006 Jun; 368(1-2):183-7. PubMed ID: 16472797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL; Malinin AI; Pokov AN; Hanley DF
    Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory markers and cardiac function in acute coronary syndrome: difference in ST-segment elevation myocardial infarction (STEMI) and in non-STEMI models.
    Di Stefano R; Di Bello V; Barsotti MC; Grigoratos C; Armani C; Dell'Omodarme M; Carpi A; Balbarini A
    Biomed Pharmacother; 2009 Dec; 63(10):773-80. PubMed ID: 19906505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial.
    Montalescot G; Sideris G; Meuleman C; Bal-dit-Sollier C; Lellouche N; Steg PG; Slama M; Milleron O; Collet JP; Henry P; Beygui F; Drouet L;
    J Am Coll Cardiol; 2006 Sep; 48(5):931-8. PubMed ID: 16949482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment.
    Bernlochner I; Steinhubl S; Braun S; Morath T; Jaitner J; Stegherr J; Mehilli J; von Beckerath N; Schömig A; Kastrati A; Sibbing D
    Thromb Haemost; 2010 Dec; 104(6):1193-200. PubMed ID: 20838744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged application of clopidogrel reduces inflammation after percutaneous coronary intervention in the porcine model.
    Ayral Y; Rauch U; Goldin-Lang P; Stellbaum C; Deiner C; Schwimmbeck PL; Schultheiss HP; Pels K
    Cardiovasc Revasc Med; 2007; 8(3):183-8. PubMed ID: 17765648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose statin and COX-2 inhibitor therapy rapidly decreases C-reactive protein level in patients with unstable angina.
    Chyrchel M; Dudek D; Bartuś S; Legutko J; Heba G; Dubiel JS
    Kardiol Pol; 2004 Sep; 61(9):213-21; discussion 222-4. PubMed ID: 15531933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent activation of nuclear factor kappa-B signaling pathway in patients with unstable angina and elevated levels of C-reactive protein evidence for a direct proinflammatory effect of azide and lipopolysaccharide-free C-reactive protein on human monocytes via nuclear factor kappa-B activation.
    Liuzzo G; Santamaria M; Biasucci LM; Narducci M; Colafrancesco V; Porto A; Brugaletta S; Pinnelli M; Rizzello V; Maseri A; Crea F
    J Am Coll Cardiol; 2007 Jan; 49(2):185-94. PubMed ID: 17222729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction.
    Fu XH; Hao QQ; Jia XW; Fan WZ; Gu XS; Wu WL; Hao GZ; Li SQ; Jiang YF; Geng W
    Chin Med J (Engl); 2008 Mar; 121(6):522-7. PubMed ID: 18364139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of percutaneous coronary intervention on inflammatory response and endothelial progenitor cell recruitment.
    Garg R; Tellez A; Alviar C; Granada J; Kleiman NS; Lev EI
    Catheter Cardiovasc Interv; 2008 Aug; 72(2):205-9. PubMed ID: 18651648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antiplatelet effect of atorvastatin in patients with acute coronary syndrome depends on the hs-CRP level.
    Vasilieva E; Kasyanova O; Shpektor A
    Acute Card Care; 2008; 10(3):181-4. PubMed ID: 18608041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.